Pharmaceutical Executive
As the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.
Mohit Jain
Advertisement
Articles by Mohit Jain
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Foundayo Under National Priority Voucher Program
2
Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals
3
Merck Enters $838 Million Research & Development Collaboration with Infinimmune
4
Eli Lilly Enters $7.8 Billion Agreement to Acquire Centessa Pharmaceuticals to Advance Sleep-Wake Treatments
5